Latest news
Attovia Therapeutics raises $332M in upsized IP... - PluangPluang · Thu, 06 Aug 2026 21:54:48 GMTAttovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:14:27 GMTImmune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 10:46:00 GMTAttovia IPO Proceeds Will Advance Three Immune-Mediated Candidates - Stock TitanStock Titan · Thu, 06 Aug 2026 09:57:00 GMTImmunotherapy Startup Attovia Lists on Nasdaq: IPO Raises $289 Million, First-Day Market Cap Tops $900 Million - finance.biggo.comfinance.biggo.com · Thu, 06 Aug 2026 08:26:00 GMTFenwick-Led Attovia Therapeutics Prices Upsized $289M IPO - Law360Law360 · Wed, 05 Aug 2026 20:58:00 GMTAttovia Therapeutics, Developer of Next‑Generation Biotherapeutics for Immune‑Mediated Diseases, Files for Nasdaq IPO - TradingViewTradingView · Wed, 05 Aug 2026 20:09:00 GMTAttovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders - MedCity NewsMedCity News · Wed, 05 Aug 2026 18:46:44 GMT